Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Brazil has enough infection data to analyze Sinovac's COVID-19 vaccine - officials

11/23/2020 | 12:04pm EST

SAO PAULO, Nov 23 (Reuters) - Brazil has gathered enough infection data from a late-stage trial of an experimental COVID-19 vaccine developed by China's Sinovac Biotech and expects to have interim results on its efficiency in early December, trial organizers said on Monday.

Dimas Covas, director of Butantan biomedical research institute that is running the late-stage trial of the Sinovac vaccine in Brazil, said it now has 74 confirmed cases among its trial participants, above the 61 initial milestone set for interim efficiency analysis.

He said an independent committee is likely to release the efficiency results in the first week of December based on its analysis of the data.

The news comes as Britain's AstraZeneca Plc on Monday joined its U.S. rivals Pfizer and Moderna and Russia in announcing positive results in pivotal trials, raising hopes that the world would soon have successful vaccines to end the pandemic.

Covas said Brazil's health ministry now has all the information needed to include Coronavac in the national program, while São Paulo Health Secretary Jean Gorinchteyn expected on Monday Brazil's regulator to approve the use of the Sinovac vaccine, CoronaVac, by January.

João Gabbardo, head of the Sao Paulo's COVID-19 contingency committee, said at the same event that he expects China's health regulator to approve Sinovac's CoronaVac in December, which could hasten approval in Brazil.

The Sinovac vaccine has been promoted by Sao Paulo Governor João Doria, a move which has put him at odds with President Jair Bolsonaro who is a vocal China skeptic.

Bolsonaro has attacked the Chinese vaccine for lacking credibility and it remains unclear whether the federal government will include it in its national inoculation program.

The ministry said on Sunday it planned to sign non-binding letters of intent to buy vaccines from Pfizer Inc, India's Bharat Biotech, the Russian Direct Investment Fund, Moderna Inc and Janssen, a unit of Johnson & Johnson , but made no mention of Sinovac's candidate. (Reporting by Eduardo Simoes and Anthony Boadle, writing by Stephen Eisenhammer; Editing by Bernadette Baum, Miyoung Kim & Shri Navaratnam)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.4.45%
DIAGNOSTICOS DA AMÉRICA S.A. -14.29% 150 End-of-day quote.102.43%
MODERNA, INC. -1.74% 130.795 Delayed Quote.27.29%
SINOPHARM GROUP CO., LTD. 0.42% 19.14 End-of-day quote.1.48%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.-6.77%
Latest news "Economy & Forex"
12:07pEquities dip, oil slides as global risk rally stalls
RE
12:07pSwiss court finds Israeli businessman Beny Steinmetz guilty of corruption
RE
12:02pBOEING : Commits to Deliver Commercial Airplanes Ready to Fly on 100% Sustainable Fuels
PU
12:01pPm trudeau says canada will clearly always have some challenges in relations with the united states, but is now starting a new era of friendly bilateral relations
RE
11:59aCanada pm trudeau says will express concern about job losses to president biden later on friday after permit for keystone xl pipeline was scrapped
RE
11:57aAmazon seeks to halt union election at Alabama warehouse
RE
11:54aOil falls as China COVID-19 cases trigger clampdowns
RE
11:53aPay business insurance claims or face enforcement, UK watchdog says
RE
11:47aEU lawmakers want Amazon, Apple, Facebook, Google CEOs at Feb. 1 hearing
RE
11:45aUK COVID-19 variant may carry higher risk of death but data limited - journalist cites advisory group
RE
Latest news "Economy & Forex"